In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia

British Journal of Clinical Pharmacology

Volumn 58, Issue 2, 2004, Pages 212-216

  Kretz, Olivier ^a,b   Weiss, H Markus ^a   Schumacher, Martin M ^a   Gross, Gerhard ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b WKL 135424   (Switzerland)

Author keywords

1 acid glycoprotein; CGP74588; Gleevec ; Glivec ; Imatinib mesylate

Indexed keywords

CARBON 14; DRUG METABOLITE; IMATINIB; OROSOMUCOID;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HEMATOCRIT; HUMAN; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RAT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; DOGS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MACACA FASCICULARIS; MALE; MICE; MIDDLE AGED; PIPERAZINES; PROTEIN BINDING; PYRIMIDINES; RATS; RATS, WISTAR;

EID: 3843135290     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02117.x     Document Type: Article

References (18)

1. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100-4.
2. Buchdunger E, O'Reilly T, Wood J. Pharmacology of imatinib (STI571). Eur J Cancer 2002; 38(Suppl 5): S28-S36.
3. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Medical 2001; 344: 1038-42.
4. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Medical 2002; 347: 472-80.
5. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-80.
6. Hui CH, Hughes TP. Strategies for the treatment of imatinib-resistant chronic myeloid leukemia. Clin Adv Hematol Oncol 2003; 1: 538-59.
7. Barthe C, Cony-Makhoul P, Melo JV, Mahon JR. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293: 2163.
8. le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95: 1758-66.
9. Gambacorti-Passerini C, Barni R le Coutre P, et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL (+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000; 92: 1641-50.
10. Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935-42.
11. Peng B, Hayes M, Resta D, et al. Clinical investigations of the pharmacokinetics and pharmacodynamics of Glivec® (imatinib) in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22: 935-42.
12. Pacifici, GM, Viani, A. Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences. Clin. Pharmacokinet 1992; 23: 449-68.
13. Fuse E, Tanii H, Takai K, et al. Altered pharmacokinetics of a novel anticancer drug UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans. Cancer Res 1999; 59: 1054-60.
14. le Coutre P, Kreuzer KA, Na IK, et al. Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cells Mol Dis 2002; 28: 75-85.
15. Gambacorti-Passerini CB, Rossi F, Verga M, et al. Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients. Blood Cells Mol Dis 2002; 28: 361-72.
16. Jorgensen HG, Elliott MA, Allan EK, Carr CE, Holyoake TL, Smith KD. Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood 2002; 99: 713-5.
17. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. alpha1 Acid Glycoprotein Binds to imatinib (STI571) and Substantially Alters Its Pharmacokinetics in Chronic Myeloid Leukemia Patients. Clin Cancer Res 2003; 9: 625-32.
18. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998; 50: 387-412.